Qyuns Therapeutics Co., Ltd. (HKG:2509)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2022	FY 2021
Period Ending	Dec 31, 2022	Dec 31, 2021
Biologic Therapies for Autoimmune and Allergic Diseases	9.66M	21.35M
Biologic Therapies for Autoimmune and Allergic Diseases Growth	-54.74%	-
Total	9.66M	21.35M
Total Growth	-54.74%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2022	FY 2021
Period Ending	Dec 31, 2022	Dec 31, 2021
The People's Republic of China (The "PRC")	9.66M	21.35M
The People's Republic of China (The "PRC") Growth	-54.74%	-
Total	9.66M	21.35M
Total Growth	-54.74%	-

Source: S&P Global Market Intelligence.